2型糖尿病のポリヌーロパシー

Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres.

Neuropathology and applied neurobiology·2013

Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia.

Neurology·2010

Myostatin and its precursor protein are increased in the skeletal muscle of patients with Type-II muscle fibre atrophy.

Folia morphologica·2008

Increased expression of Noga-A in ALS muscle biopsies is not unique for this disease.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology·2007

Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology·2006

Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers.

Neurology·2004

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

White Matter Functional Dysregulation in Amyotrophic Lateral Sclerosis: Machine Learning-Based Biomarkers and Transcriptomic Signatures.

Current neuropharmacology·2026

Combined bidirectional spinal cord stimulation for refractory neuropathic pelvic pain: a case report.

Frontiers in pain research (Lausanne, Switzerland)·2026

Neurovascular unit uncoupling in diabetic retinopathy: molecular mechanisms and stage-adapted therapeutic strategies.

Frontiers in endocrinology·2026

Late-onset ornithine transcarbamylase deficiency with neurological damage and serial brain multimodality monitoring: a case report.

Frontiers in medicine·2026

The influence of magnesium ions on the electrophysiological, analgesic, and BDNF-induced neuromodulation of morphine effects in diabetic rats.

Frontiers in pharmacology·2026

Risk factors of nasogastric tube removal failure in acute ischemic stroke patients: a 3-months follow-up cohort study at a single institute.

Frontiers in neurology·2026

関連する実験動画

2型糖尿病のポリヌーロパシー

関連する概念動画

Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres.

Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia.

Myostatin and its precursor protein are increased in the skeletal muscle of patients with Type-II muscle fibre atrophy.

Increased expression of Noga-A in ALS muscle biopsies is not unique for this disease.

Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers.

Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

White Matter Functional Dysregulation in Amyotrophic Lateral Sclerosis: Machine Learning-Based Biomarkers and Transcriptomic Signatures.

Combined bidirectional spinal cord stimulation for refractory neuropathic pelvic pain: a case report.

Neurovascular unit uncoupling in diabetic retinopathy: molecular mechanisms and stage-adapted therapeutic strategies.

Late-onset ornithine transcarbamylase deficiency with neurological damage and serial brain multimodality monitoring: a case report.

The influence of magnesium ions on the electrophysiological, analgesic, and BDNF-induced neuromodulation of morphine effects in diabetic rats.

Risk factors of nasogastric tube removal failure in acute ischemic stroke patients: a 3-months follow-up cohort study at a single institute.

関連する実験動画

2型糖尿病のポリヌーロパシー

関連する概念動画

関連記事